ArticleBMC cancer2019
A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 2 syntheses or guidelines pooled it, 366 citations in OpenAlex.
- Pooled it
- Current evidence on the relationships among five polymorphisms in the matrix metalloproteinases genes and prostate cancer risk.Scientific reports · 2024Pooled it
- A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.ACS central science · 2026Article
- 3D Bioprinted Breast Cancer-Stroma Model with Tailored Migration-Permissive Bioink Reveals Impact of Adipose-Derived Stromal Cells on Cancer Cell Migration and Invasion Dynamics.Advanced healthcare materials · 2026Article
- A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer.The FEBS journal · 2026Review
- Article
- Potential Prognostic and Metastatic Implications of MACC1 and MMP8 in Colorectal Cancer.Current issues in molecular biology · 2026Article
- Stabilin‑1: An immunoregulatory scavenger receptor in inflammation and tissue homeostasis (Review).Molecular medicine reports · 2026Review
- Prognostic stratification in non-small cell lung cancer using a TIDE-informed transcriptomic signature: model development and validation.Translational cancer research · 2026Article
- Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice.Nature communications · 2026Article
- Substrate-Mimicking Peptides as MMP-1 Inhibitors: Impact of Zinc-Binding Group Position on Ternary Complex Stability.Inorganic chemistry · 2026Article
- Hypertension and ovarian cancer risk: a meta-analysis of observational studies.Archives of medical science : AMS · 2026Review
- Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer.Cancer immunology, immunotherapy : CII · 2025Article
- The research trends and hotspots of claudins in the field of cancer.Cell adhesion & migration · 2025Review
- Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025Review
- Liriopesides B inhibits proliferation and metastasis and induces apoptosis of oral squamous cell carcinoma via the PI3K/Akt/mTOR signaling pathway.Translational cancer research · 2025Article
- Salecan Suppresses Pancreatic Cancer Progression by Promoting Necroptosis via the RIPK1/MLKL Pathway.Nutrients · 2025Article
- Targeting EGFR/IGF-IR Functional Crosstalk in 2D and 3D Triple-Negative Breast Cancer Models to Evaluate Tumor Progression.International journal of molecular sciences · 2025Article
- The function of metalloproteinases in pathophysiology of inflammatory bowel disease and colon cancer.Journal of leukocyte biology · 2025Review
- A novel defined manganese metabolism-related gene signature for predicting the prognosis of pancreatic ductal adenocarcinoma.Oncology letters · 2025Article
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
implicationBy understanding Matrix Metalloprotease (MMP) dysregulation from a pan-cancer perspective, this study sheds light on the diagnostic potentials of MMPs across multiple neoplasms.
backgroundMMPs are intriguing genes related to cancer disease progression, functional promotion of angiogenesis, invasion, metastasis, and avoidance of immune surveillance. Many studies have noted these genes are frequently upregulated in cancer. However, expression patterns of all MMPs and their diagnostic and prognostic potential have not been investigated in a pan-cancer perspective.
methodsThe Cancer Genome Atlas (TCGA) data were used to evaluate diagnostic and prognostic potential of 24 MMPs in fifteen different cancer types. Gene expression measured by RNA-seq was analyzed by differential expression, hierarchical clustering, and ROC analysis for individual genes and in combination.
resultsMMP1, MMP9, MMP10, MMP11, and MMP13 were almost universally upregulated across all cancers, with significant (p < 0.05) fold change (FC > 2) in ten of fifteen cancers. MMP3, MMP7, MMP12 and MMP14) are significantly up-regulated in at least 10 cancer types. Interestingly, MMP2, MMP7, MMP23B, MMP27 and MMP28) are significantly down-regulated in seven to nine cancer types. Multiple MMPs possess AUC's > 0.9 in more than one cancer. However, survival analyses suggest that the prognostic value of MMPs is limited to clear cell renal carcinoma.
conclusionsMost MMPs have consistently increased gene expression across cancers, while several MMPs have consistently decreased expression in several cancer types. Many MMPs have diagnostic value individually or in combination, while the prognostic value of MMPs is restricted to one subtype of kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.